RSLS +500% upside potential according to this analyst RSLS, ReShape Lifesciences, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally.
On 11/12/2021 Anthony Vendetti from Maxim Group brokerage Reiterated the Buy Rating for RSLS with a price target of $8.00.
That is more that 5X from the current price.
Looking forward to read your opinion about it.
